- Home
- FISI vs KROS Comparison
FISI vs KROS Comparison
Compare FISI & KROS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | FISI | KROS |
|---|---|---|
| Founded | 1817 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 615.8M | 655.9M |
| IPO Year | 1999 | 2020 |
Fundamental Metrics
Financial Performance| Metric | FISI | KROS |
|---|---|---|
| Price | $31.89 | $21.30 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 4 | 12 |
| Target Price | ★ $33.50 | $22.20 |
| AVG Volume (30 Days) | 128.3K | ★ 927.5K |
| Earning Date | 01-29-2026 | 11-05-2025 |
| Dividend Yield | ★ 3.89% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 1.57 |
| Revenue | $116,735,000.00 | ★ $246,718,000.00 |
| Revenue This Year | $124.17 | $6,876.34 |
| Revenue Next Year | $6.77 | N/A |
| P/E Ratio | ★ N/A | $13.58 |
| Revenue Growth | N/A | ★ 37798.31 |
| 52 Week Low | $20.97 | $9.12 |
| 52 Week High | $33.00 | $22.55 |
Technical Indicators
Market Signals| Indicator | FISI | KROS |
|---|---|---|
| Relative Strength Index (RSI) | 59.59 | 64.94 |
| Support Level | $31.85 | $19.76 |
| Resistance Level | $32.72 | $21.76 |
| Average True Range (ATR) | 0.59 | 0.90 |
| MACD | -0.12 | -0.10 |
| Stochastic Oscillator | 49.31 | 57.35 |
Price Performance
Historical ComparisonAbout FISI Financial Institutions Inc.
Financial Institutions Inc operates as a financial holding company, engages in the provision of a wide range of consumer and commercial banking services to individuals, municipalities, and businesses in Western and Central New York. It operates through one segment: The Banking segment which includes all of the company's retail and commercial banking operations.
About KROS Keros Therapeutics Inc.
Keros Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from hematological, pulmonary, and cardiovascular disorders with high unmet medical needs. The company's protein therapeutic product candidate, KER-050, is being developed for the treatment of low blood cells counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, or MDS, and in patients with myelofibrosis.